Scalp-Injected RNA Hair Loss Drug Completes Phase 1b Dosing in Australia
OliX announced on August 4 that it has completed patient dosing in the Australian Phase 1b clinical trial for OLX104C (compound name: OLX72021), an...
Search results for "biotech"
Forget Wegovy and Mounjaro: How Hanmi’s 'EPPE' Is Redefining Obesity Care
Hanmi Pharmaceutical has officially named its in-development obesity treatment "EPPE." Derived from the opening of its international nonproprietary...
Olix Obesity Candidate Reduces Monkeys’ Visceral Fat by 29.2%, Outperforming Global Rival
Olix announced on July 30 that its obesity drug candidate, "OLX501A," significantly outperformed a global rival...
South Korea Ranks in GSK’s Global Top 10 for Clinical Research, with Over 70 Trials Underway
"South Korea is among the top 10 markets in GSK’s global clinical research. More than 70 clinical programs are...
GSK Wins Early FDA Approval for Oral Lung Cancer Drug Jideytro Following $10.6 Billion Nuvalent Acquisition
A new oral therapy is now available for patients with ROS1-positive lung cancer whose disease has progressed following...
Daegu Wins Bid to Host 2034 World Congress of Basic & Clinical Pharmacology
Daegu has been selected to host the 2034 World Congress of Basic & Clinical Pharmacology (WCP 2034), marking the first...
Biogen Korea Taps Pharma Veteran Kim Chul-woong as New Country Lead
Biogen Korea has appointed Kim Chul-woong as its new general manager, tapping an executive with extensive expertise in...
ITZY’s Yuna Showcases Sculpted Silhouette: The Core and Glute Workout Behind Her Look
ITZY member Yuna recently offered a glimpse into the dedication behind her celebrated hourglass silhouette.
United Therapeutics Acquires Thymmune, Betting 460 Billion Won on Thymus Cell Therapy
The race to develop regenerative cell therapies for an ultra-rare disease that leaves patients born without a...
ABL Bio’s Stomach Cancer Drug Shows Promise in Once 'Untreatable' Patients
South Korean platform biotech company ABL Bio announced that development remains firmly on track despite investor...